PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
11.35%
Net income growth 1.25-1.5x TRVN's 9.25%. Bruce Berkowitz would verify whether cost discipline or revenue gains drive the outperformance.
1.31%
Some D&A expansion while TRVN is negative at -0.67%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-12.55%
Negative yoy SBC while TRVN is 5.17%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-199.74%
Negative yoy working capital usage while TRVN is 121.34%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
AP growth well above TRVN's 100.00%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-382.74%
Negative yoy usage while TRVN is 174.33%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-25.35%
Both negative yoy, with TRVN at -22.76%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
2.31%
Operating cash flow growth below 50% of TRVN's 60.72%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
83.69%
CapEx growth of 83.69% while TRVN is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
83.69%
Lower net investing outflow yoy vs. TRVN's 189.28%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
3875.79%
We slightly raise equity while TRVN is negative at -100.00%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.